FindTrial
Sign In

Bivalirudin versus Unfractionated Heparin during Percutaneous Coronary Intervention in Patients at High Risk of Bleeding with Acute Coronary Syndrome in Contemporary Practice

Bivalirudin versus Unfractionated Heparin during Percutaneous Coronary Intervention in Patients at High Risk of Bleeding with Acute Coronary Syndrome in Contemporary Practice

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000034771
Enrollment
Unknown
Registered
2020-07-18
Start date
2020-08-01
Completion date
Unknown
Last updated
2020-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary atherosclerotic heart disease

Interventions

Bivalirudin versus unfractionated heparin:N/A

Sponsors

The First Affiliated Hospital of Zhengzhou University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: (1) Patients aged >= 18 years who underwent PCI at the First Affiliated Hospital of Zhengzhou University from January to September 2019. (2) Patients had a high risk of bleeding and acute coronary syndrome. (3) Patients received bivalirudin or unfractionated heparin during PCI.

Exclusion criteria

Exclusion criteria: Nil

Design outcomes

Primary

MeasureTime frame
net adverse clinical events;—

Secondary

MeasureTime frame
major adverse cardiovascular events;myocardial infarction;all-cause mortality;stroke;major bleeding;??????;urgent target vessel revascularization;—

Countries

China

Contacts

Public ContactKui Chen

The First Affiliated Hospital of Zhengzhou University

fccchenk@zzu.edu.cn+86 13803859349

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 23, 2026